MAP2K7 and familial pancreatic carcinoma: After investigating the mechanism of resistance of pancreatic cancer to imatinib treatment, Takayama et al. [83] reported that treatment with 5 μM imatinib failed to suppress pancreatic cancer cell growth, but it is speculated that the MEK–MAPK pathway is responsible for the resistance of pancreatic cancer to imatinib.